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Nitric oxide (NO) is an intra- and extracellular messenger that mediates diverse signaling pathways in target cells and is known
to play an important role in many physiological processes including neuronal signaling, immune response, inﬂammatory response,
modulation of ion channels, phagocytic defense mechanism, penile erection, and cardiovascular homeostasis and its decompensation
inatherogenesis.RecentstudieshavealsorevealedaroleforNOassignalingmoleculeinplant,asitactivatesvariousdefensegenesand
acts as developmental regulator. In plants, NO can also be produced by nitrate reductase. NO can operate through posttranslational
modiﬁcation of proteins (nitrosylation). NO is also a causative agent in various pathophysiological abnormalities. One of the very
important systems, the cardiovascular system, is aﬀected by NO production, as this bioactive molecule is involved in the regulation of
cardiovascular motor tone, modulation of myocardial contractivity, control of cell proliferation, and inhibition of platelet activation,
aggregation,andadhesion.TheprimesourceofNOinthecardiovascularsystemisendothelialNOsynthase,whichistightlyregulated
with respect to activity and localization. The inhibition of chronic NO synthesis leads to neurogenic and arterial hypertensions, which
later contribute to development of myocardial ﬁbrosis. Overall, the modulation of NO synthesis is associated with hypertension.
This review brieﬂy describes the physiology of NO, its synthesis, catabolism, and targeting, the mechanism of NO action, and the
pharmacological role of NO with special reference to its essential role in hypertension.
INTRODUCTION
Nitric oxide (NO), ﬁrst characterized as an endotheli-
um-derived relaxation factor, has now emerged as a ubiq-
uitous signaling messenger molecule involved in diverse
pathophysiologic processes such as neurotransmission,
inﬂammatory and immune responses, and vascular
homeostasis [1, 2, 3, 4]. It is a highly diﬀusible inor-
ganic radical gas and has been known for many years as
a noxious pollutant in car exhaust fumes, fossil fumes,
and cigarette smoke. It is also known to bind cytochrome
oxidase, the terminal enzyme in the mitochondrial elec-
trontransportchain.However,therelevanceofthisaction
onlybecameapparentafterthediscoveryinthe1980s that
NO is a biological mediator, and the demonstration in
the 1990s that it inhibits respiration in mammalian cells.
TherolesofNOintheregulationofcellbioenergetics,cell
death, and controlling oxygen supply and demand for cell
integrity were also suggested [4, 5]. In this context, NO
coordinates the respiratory cycle to acquire and deliver
oxygen to target tissues by regulating hemoglobin (Hb)
function and vascular smooth muscle contractility [4].
NOissynthesizedfromtheaminoacidL-argininebya
family of enzymes termed NO synthases (NOS). NO, syn-
thesized in neurons of the central nervous system, acts as
a neuromediator with many physiological functions, in-
cluding the formation of memory, coordination between
neuronal activity and blood ﬂow, and modulation of pain
[6]. In peripheral nervous system, NO is released by a
widespreadnetworkofnerves,whichmediatesomeforms
ofneurologicvasodilatationandregulatecertaingastroin-
testinal, respiratory, and genitourinary functions [7]. NO
is also generated in large quantities during host defense
and immunological reactions, where it contributes to228 Narendra Tuteja et al 2004:4 (2004)
their cytotoxicity against tumor cells, bacteria, viruses,
and other invading microorganisms [8, 9]. NO is a bi-
atomic free radical (uncharged molecule) containing an
unpaired electron that may undergo several reactions act-
ing either as a weak oxidant or as a reductant compound
[10]. Three biological and interrelated active redox forms
of NO have been described, namely, NO, nitrosonium
(NO+), and nitroxyl anion (NO−)[ 11]. NO can react
with oxygen free radicals to form powerful oxidant per-
oxynitrite (ONOO−), which is involved in protein oxida-
tion reactions under physiological conditions [12]. NO or
NO+ ion is also able to form S-nitrosothiols (RSNO) by
reacting with sulphydryl groups of protein, which are po-
tent platelet aggregation inhibitors and vasorelaxantcom-
pounds.
Recent studies have also revealed a role of NO as a
signaling molecule in plants. As a developmental regula-
tor, NO promotes germination, leaf extension, and root
growth, and delays leaf senescence and fruit maturation.
Moreover,NOactsasakeysignalinplantresistancetoin-
compatible pathogens by triggering resistance-associated
hypersensitivecelldeath.Inaddition,NOactivatestheex-
pressionofseveraldefensegenes(eg,pathogenesis-related
genes, phenylalanine ammonia-lyase, chalcone synthase)
and could play a role in pathways leading to systemic ac-
quired resistance [13]. A novel role for NO in the reg-
ulation of lateral root development in tomato has been
reported, which probably operates in the auxin signaling
transduction pathway [14]. NO has been associated with
plant defense responses during microbial attack, and with
induction and/or regulation of programmed cell death
[15].
Studies have indicated that chronic administration of
Nomega-nitro-L-argininemethylester(L-NAME),anin-
hibitor of NO synthesis, produces marked hypertension.
Although the mechanism of this form of hypertension is
not well understood, several studies have demonstrated
that sympathetic nerve activity is at least acutely elevated
after L-NAME administration [16]. Now it is known that
hypertensions are linked to the alteration in NO concen-
tration. In this review, we describe the interaction of NO
with superoxide anion, the physiology of NO, its syn-
thesis/catabolism/targeting,themechanismofNOaction,
andthepharmacologicalroleofNOwithspecialemphasis
on its essential role in hypertension.
INTERACTION OF NITRIC OXIDE WITH SUPEROXIDE
ANION AND OTHER RADICALS
Besides the role of NO in hypertension and cardiovas-
cular disease, the free radical (eg, superoxide anion) has
been reported to play a role in endothelial dysfunction.
Free radicals are chemical species (molecules or atoms)
possessing an unpaired electron in their outermost or-
bital. Due to the presence of one or more unpaired elec-
trons, these species are paramagnetic, which makes them
highlyreactive.Afreeradicalcanbeformedinamolecule,
by gaining an additional electron, for example, reduction
of molecular oxygen (O2) to the superoxide anion radical
(O
−·
2 )[ 17]:
O2 +e− −→ O−·
2 . (1)
Some oxides of nitrogen (NO·,N O
·
2) are also free radi-
cals. In the absence of L-arginine, nNOS has been shown
to generate superoxide, O
−·
2 .Superoxide,eitherdirectlyor
through its self-dismutation to hydrogen peroxide H2O2,
is likewise believed to be a cell-signaling agent. It has
been estimated that a typical human cell metabolizes
about 1012 molecules of O2 per day and generates 3 × 109
molecules of H2O2 per hour. In oxidative stress condition
O
−·
2 is an unusual species, where it can act as a reducing
agent by donating its extra electron to NO to form perox-
ynitrite (ONOO−), or it can act as an oxidizing agent; in
this case it gets reduced to H2O2. Under normal circum-
stances, the relatively high abundance of superoxide dis-
mutase(SOD)ensuresthatthelatterreactionoccurspref-
erentially.However,whenNOisproducedinlargequanti-
ties,asigniﬁcantamountofO2 reactswithNOtoproduce
ONOO−:
O−·
2 +NO−→ ONOO−,
O−·
2 +2 H−→ H2O2 +3 O 2.
(2)
The NO· radical can react with peroxyl radical (RO
·
2), hy-
droxyl radical (OH·), or NO−, (a reactive and short-lived
species) to produce alkyl peroxinitrite (ROONO), nitrous
acid (HNO2), or nitrous oxide (N2O), respectively:
NO· +R O ·
2 −→ ROONO,
NO· +OH · −→ HNO2,
NO· +NO − −→ ONNO−·,
NO· +ONNO−· −→ NO−
2 +N 2O,
ONNO
−· +H + −→ OH
· +N 2O.
(3)
On exposure to air, NO reacts with O2 to form the brown
gas nitrogen dioxide (NO
·
2), which is far more reactive
than NO·. The overall reaction is
2NO· +O 2 −→ 2NO·
2. (4)
The oxidation of NO· dissolved in aqueous solutions pro-
duces mainly nitrite ion (NO
−
2 ); the overall equation is
4NO
· +O 2 +2 H 2O −→ 4H+ +4 NO
−
2 . (5)
The above reaction may be the sum of the equations
2NO
· +O 2 −→ 2NO
·
2,
2NO
·
2 +2 NO
· −→ N2O3 (addition of 2 radicals),
N2O3 +2OH
− −→ H2O+2 N O
−
2 .
(6)
The role of NO, H2O2,a n dO
−·
2 in regulation of
spontaneous tone in aorta of deoxycorticosterone acetate
(DOCA)-salt hypertensive rats has been reported [18].
TheNO
·
2,ONOOH,N 2O3, andHNO2 canproducenitra-
tion, nitrosation, and deamination of DNA bases, which
can make the DNA unstable.2004:4 (2004) Nitric Oxide in Physiology and Pathophysiology 229
PHYSIOLOGY OF NITRIC OXIDE
The interest in NO arose because it plays many im-
portant physiological roles in the nervous system, the
vascular system, and other systems (eg, penile erection,
bladder control, lung vasodilation, and peristalsis). The
physiological stimuli for generation of NO are not fully
understood, but pulsatile ﬂow and shear stress may be
the main determinants [19]. Griﬃth and Edwards [20]
demonstrated that the activity of endogenous NO was
much more in large arterioles in which hydraulic resis-
tance and sheer stress were also highest. The NO was
known to be released from endothelial cells in culture in
a ﬂow-dependent manner [21] .T h er o l eo fo t h e rf a c t o r s
such as sympathetic or parasympathetic involvement in
the generation of NO or whether some endothelial cells
releases vasoactive substances, which in turn induce the
release of NO, has not been yet established. NO is not
storedanddiﬀusesfreelytoitssiteofactionwhereitbinds
covalently to its eﬀectors. In biological systems, it has an
estimated half-life of only 3–5 seconds. In coronary artery
disease, the basal level of NO as well as stimulated release
of NO were reduced [21]. The Hb-mediated inhibition of
NO may play a role in the vasospasm that follows sub-
arachnoid hemorrhage, which has long been suspected
to be mediated by some product of lysed red blood cells
[22]. Since NO is also the inhibitor of platelet activation,
any alteration of its formation in the vessel wall will not
only predispose to vasoconstriction but will also favor
platelet adhesion and aggregation. In this context, platelet
products released during aggregation in vivo may cause
contraction of de-endothelialized canine coronary artery
rings, whereas they induce relaxation in presence of en-
dothelium [23]. Interestingly, isosorbide dinitrate, which
releases NO, and prostaglandin E acted synergistically to
reduce platelet deposition and to increase their survival
time in patients with peripheral vascular disease [24].
The modulation of ion channels, including Ca2+
channels and pores, is now emerging as a general mech-
anism by which NO exerts biological signaling. Due
to the fact that the bioactivity of NO involves several
second-messenger systems and is profoundly inﬂuenced
bymultipleenvironmentalstimuli,manyseeminglydiver-
gent observations may be found in the literature [25]. Ac-
cordingly, there is an ongoing controversy regarding the
impact of NO on Ca2+ channels. An important theme
for NO signaling, which may partly settle the ongo-
ing controversies regarding it, is the spatial conﬁnement
of NOSs with eﬀector molecules, including ion chan-
nels. Perhaps the most important environmental stimu-
lus that inﬂuences the bioactivity of NO is redox milieu,
which in turn is inﬂuenced by the formation of reactive
oxygen species and oxygen tension. Recently Khan and
Hare [25] have reviewed the current knowledge regarding
the NOS modulation of Ca2+ channels, emphasizing the
cardiovascular, musculoskeletal, and central nervous sys-
tems. Ruiz-Stewart et al [26] have recently demonstrated
that soluble guanylyl cyclase (sGC) is a nucleotide sensor
whose responsiveness to NO is regulated by ATP.
NITRIC OXIDE SYNTHESIS
NO is mainly synthesized in living organisms by the
action of a group of enzymes called NOSs which convert
the amino acid L-arginine into NO and another amino
acid, L-citrulline. Oxygen is required and the NOSs con-
tain four cofactors: FAD, FMN, tetrahydrobiopterin, and
haem; the haem center has spectral properties resem-
bling those of cytochrome P450. There are three types
of NOSs. Two are constitutive (named cNOS) and one
is inducible by cytokines and endotoxins (named iNOS).
There are two subtypes of cNOS: one was initially de-
tected in the vascular endothelium and named eNOS and
the other is present in the central and peripheral nervous
systems and named nNOS [5]. The nNOS and iNOS are
predominantly soluble enzymes whereas eNOS is more
than 90% particulate [27]. The nNOS and eNOS are
Ca2+/calmodulin-dependent enzymes [28].
TheiNOSreleasesNOinlargequantities(micromolar
range) during inﬂammatory or immunological defense
reactions and is involved in host tissue damage. The over-
expression of iNOS gene might account for NO overpro-
duction, as it is reported in rats with portal hypertension
[29].TheiNOSsbindcalmodulintightlyandtheiractivity
is essentially Ca2+-independent. Miljkovic and Trajkovic
[30] have shown that iNOS is activated by interleukin-
17 (IL-17), which is a proinﬂammatory T cell cytokine.
They have also proposed the biological consequences of
IL-17-mediated NO release that could be relevant to the
mechanisms or therapy of autoimmune and inﬂamma-
tory disorders [30].
The eNOS is expressed constitutively in endothelial
cells and synthesizes the NO needed for regulation of
blood pressure. The activation of eNOS is induced by in-
crease in intracellular Ca2+ resulting from activation of
diverseG-protein-coupledreceptors(GPCR)orfrommo-
bilization of intracellular Ca2+ stores. Studies have shown
that thapsigargin, a selective inhibitor of Ca-ATPase of
endoplasmic reticulum and sarcoplasmic reticulum, acti-
vates NO release from pulmonary artery endothelial cells
[31]. The actual intracellular Ca2+ that is required to ac-
tivate this enzyme may be signiﬁcantly diﬀerent from
that released from subcellular compartments as well as
the average Ca2+ concentration [32]. Recently, Liu et al
[33]havedemonstratedthatEndothelin-1activateseNOS
via heterotrimeric G-protein beta-gamma subunit signal-
ing to protein kinase B/Akt. An increase in the associ-
ation of heat shock protein 90 (HSP90) with eNOS is
well recognized for increasing NO (NO·) production. De-
spite the progress in this ﬁeld, the mechanisms by which
HSP90 modulates eNOS remain unclear. It has recently
been suggested by Ou et al [34] that the tyrosine kinase
and HSP90-dependent signaling pathways act in concert
to suppress uncoupled eNOS activity.230 Narendra Tuteja et al 2004:4 (2004)
The nNOS is found in a variety of neurons in both
the central and peripheral nervous systems and is a con-
stitutionally expressed enzyme, though it can also be in-
duced in neurons by certain treatments. Lately, Raines et
al [35] examined the activation of cellular signal trans-
duction pathways in nNOS-transfected cells grown in the
presence or absence of L-arginine. Their results indicated
that nNOS can diﬀerentially regulate the ERK (extracellu-
lar signal-regulated kinase) signal transduction pathway
in a manner dependent on the presence of L-arginine and
the production of NO.
NITRIC OXIDE CATABOLISM
A strict regulation of bioactivity of NO is essential
for maintaining vasculature tone and inhibiting platelet
activation. Several mechanisms appear to operate for
the degradation of NO. Liu et al [36] have shown that
erythrocyte sequestration of oxyhemoglobin and ﬂow
properties of erythrocytes decreased the reaction of NO
with hemoglobin. Uric acid, the product of free radical
generating enzyme, xanthine oxidase, has been shown to
be the sink for NO activity [32]. In hypertensive state, su-
peroxideanionreactswithNOandformsONOO−,which
accounts for the removal of NO. There are also reports
to show the existence of some enzymatic scavengers of
NO. For example, Abu-Soud and Hazen [37]o b s e r v e d
that NO serves as the substrate for multiple members
of mammalian peroxidase family. Another possible enzy-
matic mechanism of NO catabolism is via catalytic con-
sumption by prostaglandin H synthase [38].
NITRIC OXIDE TARGETING
The smooth muscles are the target for NO produced
from endothelial cells, but the route and chemical form
of NO have been controversial. The assumption that dif-
fusion alone moves NO is no more feasible. Pawloski
et al [39] have suggested that the movement of NO
through erythrocytes occurs by a precisely coordinated
series of events. Pawloski et al [39] have shown that the
RBCs do not consume NO irreversibly by combining with
H b .N Or e e m e r g e sf r o mR B C sa sb i o l o g i c a l l ya c t i v eS -
nitrosothiol, which is protected from reacting with Hb.
Some of the NO captured by Fe2+ in Hb can be shut-
tled intramolecularly to a conserved thiol group, produc-
ing S-nitrosohemoglobin. This NO may be transferred
to other thiol-containing molecule, thus enabling NO
activity to leave RBCs. This has been shown to occur pref-
erentially in oxygen-poor tissues where Hb changes con-
formation.
MECHANISM OF NITRIC OXIDE ACTION
A variety of stimuli such as 5-hydroxytryptamine,
acetylcholine, thrombin, calcium ionophore A23187, and
arachidonic acid cause changes in arterial pressure and
electrical stimulation and are able to release NO from en-
dothelialcells[40].ThestabilityofNOislowerthanother
powerful endothelial vasodilators such as prostacyclin,
which together with NO causes platelet antiaggregation
and vasorelaxation eﬀects by diﬀerent mechanism [41].
NO is known to readily bind certain transition metal ions
and many of its physiological eﬀects are exerted as a result
of its initial binding to Fe2+ haem groups in the enzyme
guanylate cyclase. As a result, the enzyme becomes active
and catalyses the production of more cGMP from GTP.
This cGMP lowers the intracellular Ca2+ and relaxes the
muscles, dilating the vessel and lowering blood pressure.
Endothelial-derived NO can also diﬀuse into the lumen
of the vessel, where it can prevent platelet aggregation
and adhesion to the endothelium by a cGMP-dependent
mechanism. NO and its receptor, sGC, are emerging as
key mediators coordinating ATP supply and demand. The
mechanisms coupling this pathway with metabolic and
energetic signaling remain undeﬁned. Ruiz-Stewart et al
[26] have demonstrated that sGC is a nucleotide sen-
sor whose responsiveness to NO is regulated by ATP. It
has been observed that NO stimulates ADP ribosylation
of many soluble and membrane-bound proteins includ-
ing G-proteins in vascular smooth muscles. This leads to
the activation of adenylate cyclase activity and inhibition
of phospholipase-C activity leading to vasodilation [42].
They hypothesized that in hypertensive state, the chroni-
cally decreased levels of NO lead to decreased ribosylation
of G-proteins leading to vasoconstriction.
Recent insights into molecular mechanisms regulat-
ing NO generation and the rich diversity of mechanisms
by which it propagates signals reveal the role of this sim-
ple gas as a principle mediator of systems integration of
oxygen balance. NO reversibly regulates protein function
by posttranslational modiﬁcation of cysteine thiols by S-
nitrosylation in a fashion analogous to protein phospho-
rylation. S-nitrosylation can be mediated by NO deriva-
tives including nitrosylated transition metals, NO carriers
such as nitrosothiols, or by direct interaction with NO
in the presence of electron acceptors [43]. Like phos-
phorylation, S-nitrosylation is precisely targeted to se-
lect cysteine residues in the context of speciﬁc structural
motifs within proteins. Target cysteines located between
acidic and basic amino acids that support the general
acid/base chemistry underlying S-nitrosylation confer a
guanine nucleotide exchange factor-like eﬀect to p21Ras
and activate CNG channels in the brain [4]. Moreover, S-
nitrosylationcreatesopportunitiesfornovelproteininter-
actions that could impact the composition of intracellular
signaling networks [4].
In endothelial cells, NO production activated by spe-
ciﬁc receptor agonists, shear stress, or hypoxia regulates
local hemodynamics by inducing vascular smooth muscle
relaxation [44]. Cotranslational modiﬁcation by myris-
toylation and palmitoylation compartmentalizes eNOS in
caveolae,specializedplasmamembranedomainsenriched
in caveolins, which organize molecules to control the
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resting state, association with caveolins inactivates eNOS,
inpart,bypreventingcalmodulinassociation.Theimpor-
tance of controlling the spatial and temporal characteris-
tics of NO signaling by subcellular compartmentalization
with select coregulatory molecules is highlighted by the
ability of NO to activate opposing molecular mechanisms
in the same cell [4]. Thus, cardiomyocyte ionotropy re-
ﬂectstheintegrationofeNOSsignalingincaveolae,which
reduces contractility by preventing calcium entry medi-
ated by colocalized adrenergic receptors and L-type cal-
cium channels, and nNOS signaling in sarcoplasmic retic-
ulum, which promotes contractility by S-nitrosylation of
ryanodine receptors, promoting calcium release [4, 45].
PHARMACOLOGICAL ROLE OF NITRIC OXIDE
Many pharmacological roles of NO have been re-
ported. We are describing only a few important roles. The
generation of NO in cardiovascular system is dependent
on a constant active vasodilation. The vasodilation action
of glyceryl trinitrate (GTN) was earlier believed to be due
to its conversion in the circulation to NO2,w h i c h ,i nc o n -
trast to NO3,h a ss o m ev a s o d i l a t o ra c t i o n .H o w e v e r ,i n
1940, Kranz et al [46] demonstrated that an immediate
and total conversion in the bloodstream of an eﬀective
vasodilator dose of GTN would not yield suﬃcient NO2
to explain the observed vasodilation. It is known that all
the nitrovasodilators and NO activated the sGC, which
increases the cGMP levels in smooth muscle, which in
turn induces a sequence of protein phosphorylation asso-
ciated with smooth muscle relaxation. Feelisch et al [47]
have shown that nitrovasodilators also generate NO in
a nonenzymatic reaction with cysteine. Prostacyclin and
NO act synergistically to inhibit aggregation of platelets
[48], suggesting that the release of NO and prostacyclin
by the vascular endothelium play a role in its thrombo-
resistance.
NO is implicated to play a role in penile erection. The
neurogenic NO is considered the most important factor
for relaxation of penile vessels and corpus cavernosum. In
erectile dysfunction, NO donors have a direct action on
penile tissue facilitating penile smooth muscle relaxation
[49]. The defective eNOS-driven NO synthesis causes in-
sulin resistance, arterial hypertension, and dyslipidemia
in mice, and characterizes insulin-resistant humans. On
the other hand, stimulation of iNOS and NO overpro-
duction in mice may also cause metabolic insulin resis-
tance, suggesting the eﬀect of NO in the regulation of
glucose homeostasis. Cook and Scherrer [50]r e v i e w e d
the evidence for this novel concept and provided the
conceptual framework for the use of NO-delivery drugs
and pharmacological agents that modulate the bioavail-
ability of endogenously produced NO for the treatment
of insulin resistance. A drug, Resveratrol (trans-3,4 ,5-
trihydroxystilbene), a recently described grape-derived
polyphenolic antioxidant, has been found to protect the
heart from ischemic reperfusion injury. Hattori et al [51]
have demonstrated that Resveratrol can pharmacologi-
cally precondition the heart in a NO-dependent manner.
T h er o l eo fN Oi nn e u r o n a ld e g e n e r a t i o no fgl a u c o m a
is well established, and drugs to inhibit NO production
have been introduced in preclinical studies. Giuﬀrida et
al [52] have investigated the pharmacological eﬃcacy of
a topical formulation of the nonselective NOS inhibitor,
nitro-L-arginine methyl ester (L-NAME), in an experi-
mental model of glaucoma in rabbits. They have provided
the ﬁrst evidence that topical L-NAME signiﬁcantly re-
duces the IOP in a model of ocular hypertension. Pearse
et al [53] have indicated that acute inhibition of iNOS
is beneﬁcial in reducing several patho-physiological pro-
cesses after spinal cord injury. Furthermore, they demon-
strated that the antisense inhibition of iNOS is more eﬃ-
cacious than currently available pharmacological agents.
NO is also known to mediate many pharmacological
actions of ethanol. Boyadjieva et al [54]h a v ed e t e r -
mined the role of NO in ethanol regulation of beta-
endorphin (beta-EP) release from primary cultures of
rat fetal mediobasal hypothalamic cells. Alcohol treat-
ments blocked sodium-nitroprusside-induced increases
in the level of cellular cyclic guanidine monophos-
phate. The nonspeciﬁc NO blocker NG-L-NAME, but not
the inactive isomer N-nitro-d-arginine-methyl-ester (d-
NAME), inhibited ethanol inhibitory actions on beta-EP
release. These results suggested that the cyclic guanidine
monophosphate/NO pathway is involved in ethanol alter-
ation of hypothalamic beta-EP release.
NO modulates many behavioral and neuroendocrine
responses. Genetic or pharmacological inhibition of the
synthetic enzyme that produces NO in neurons evokes
elevated and sustained aggression in male mice. NO ap-
pears to play an important role in normal brain 5-
hydroxytryptamine (5-HT, serotonin) function and may
have signiﬁcant implications for the treatment of psychi-
atric disorders characterized by aggressive and impulsive
behavior [55]. Shortly after the invention of nitro-
glycerine (NTG), it was noticed that this substance is
capable of inducing a violent headache. Only recently,
it became known that this is due to the release of NO
by NTG. As the molecular mechanism of migraine pain
remains to be determined, NTG, being prodrug of NO,
has been used to study the etiology and pathophysiology
of migraine. Such studies on NTG- and also histamine-
induced headaches have led to proposals that NO may be
the causative molecule in migraine pain. The importance
of NO as a potential initiator of the migraine attack opens
new directions for the pharmacological treatment of mi-
graine and other vascular headaches [56].
Mechanisms involved in the protective action of NO
in insulin producing cells are a matter of debate. It was
previously shown that pharmacological inhibition of c-
Src cancels the antiapoptotic action of low and sus-
tained concentrations of exogenous NO. Recently, Tejedo
et al [57] have shown that NO triggers the PI3K/Akt
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arousing Src to activate IRS-1. Schizophrenia-like symp-
tomscanbeinducedinhumansbyphencyclidine(PCP),a
drug with marked psychotomimetic properties. PCP dis-
rupts prepulse inhibition of acoustic startle in rodents, a
measure which has also been shown to be disrupted in
schizophrenic patients. This eﬀect is blocked by NOS in-
hibitors, suggesting that NO plays an important role in
this eﬀect of PCP. Methylene blue, a guanylate cyclase and
NOS inhibitor, has shown therapeutic value as an ad-
juvant to conventional antipsychotics in the therapy of
schizophrenia. Recently, Klamer et al [58]h a v es u g g e s t e d
that the NOS/guanylate cyclase pathway is involved in
pharmacological and behavioral eﬀects of PCP. Since PCP
as well exerts psychotomimetic characteristics, agents that
interfere with the NOS/guanylate cyclase pathway may be
oftherapeuticvaluealsointhetreatmentofschizophrenia
[58].
NO, xenon, and cyclopropane are anesthetic gases
that have a distinct pharmacological proﬁle. Whereas the
molecular basis for their anesthetic actions remains un-
c l e a r ,t h e yb e h a v ev e r yd i ﬀerently to most other gen-
eral anesthetics in that they have little or no eﬀect on
GABA(A) receptors, yet strongly inhibit the N-methyl-d-
aspartate subtype of glutamate receptors. It is shown that
certain members of the two-pore domain K+ channel su-
perfamilymayrepresentanimportantnewtargetforthese
gaseous anesthetics [59].
Angiotensin converting enzyme (ACE) inhibitors in-
hibit the degradation of bradykinin and contribute to ac-
cumulation of bradykinin and NO, both of which may
be beneﬁcial for diseased hearts. Since ACE produces an-
giotensin II in the heart, ACE inhibitors (ACEIs) may
prevent coronary vasoconstriction and increase coronary
blood ﬂow. On the other hand, since ACEIs also in-
hibit kininase II, which results in reduced degradation
of bradykinin, ACEIs may increase cardiac NO levels via
stimulation of bradykinin receptors and the accumula-
tion of bradykinin in the ischemic myocardium [60]. Ki-
takaze et al [61] also suggested that ACEIs attenuate both
reversible and irreversible myocardial cellular injury via
bradykinin/NO-dependent mechanisms.
Renin-angiotensin-aldosterone systems play a critical
role in the development and progression of cardiovas-
cular diseases, and ACEIs have proven eﬀective for the
treatment of these diseases. Since angiotensin II recep-
tor antagonists can inhibit the eﬀects of angiotensin II via
ACE-independent pathways, for example, chymase, they
were considered to be more eﬀective than ACEIs. On the
otherhand,ACEIscanincreasebradykinin,andthus,NO,
which may cause potent cardioprotection, inhibition of
smooth muscle proliferation, and attenuation of inﬂam-
mation mechanisms. It appears that angiotensin II recep-
tor antagonists and ACEIs may mediate cardioprotection
in diﬀerent ways [62]. ACEIs have been used extensively
in heart failure, where they induce systemic vasodilata-
tion and they have also been shown to reduce ischemic
events after myocardial infarction, although their mecha-
nisms of action on the coronary circulation are less well
understood. The ACEI, enalaprilat, improves transmural
myocardial perfusion at rest and after chronotropic stress,
and restores impaired subendocardial coronary ﬂow and
vasodilator reserve in dilated cardiomyopathy (DCM).
The eﬀects of enalaprilat were bradykinin mediated and
NO dependent and were not recapitulated by AT1 antag-
onist losartan. These data suggested beneﬁcial eﬀects of
ACEIs on the coronary circulation in DCM that are not
shared by AT1 receptor antagonists [63].
ROLE OF NITRIC OXIDE IN HYPERTENSION
There are several challenges in the study of the role of
NO pathway in hypertension. Hypertensive patients have
been shown by some, but not all, to have a reduced va-
sodilatory response to various stimuli of NO release. In
hypertension, morphological vascular alteration aﬀecting
the endothelium, the intima, and vascular smooth mus-
cle cells is produced. Thus, changes in the size and shape
of endothelial cells, as well as in endothelial replication,
have been noted. Abnormalities of endothelial cells are
considered the main factors responsible for the enhance-
ment of total systemic vascular resistance, leading to an
increase in arterial blood pressure [64]. Genetic alteration
can produce a predominant formation of endothelium-
derived contracting factors and mitogen, which enhance
the contraction elicited by vasoconstrictors and decrease
the lumen area. Among the contracting substances pro-
duced by the endothelium are O
−·
2 , thromboxane A2,a n d
peptides named endothelin [65]. Endothelin-1 is a po-
tent vasoconstrictor agent formed from a less active in-
termediate, proendothelin [65]. A signiﬁcant increase in
endothelin-1plasmaconcentrationisobservedinpatients
with primary hypertension compared with normal sub-
jects. A deﬁnite correlation has been established between
the activities of free radical generating enzymes and the
levels of NO. Mitogenetic activation described in hyper-
tension is induced by (1) an increase in sympathetic ac-
tivity [66]a n d( 2 )t h er e l e a s eo fv a s o a c t i v ea g e n t ss u c h
as endothelins, angiotensin II, prostaglandin, thrombox-
ane, transforming growth factor β, and platelet-derived
growth factor, that may additionally modulate vascular
growth [67].
In diﬀerent animal models of hypertension as well
as in hypertensive patients, a reduction of endothelium-
dependent relaxation has been reported [68]. The impair-
ment of endothelium-dependent relaxation seems to be
secondary to sustained hypertension, the intensity and
the duration of hypertension being the determining fac-
tors for the degree of impairment [69]. Luscher [70]h a s
indicated that endothelial dysfunction is a consequence,
and not a cause, of hypertension, though some studies
describe an endothelial alteration at an early age. In iso-
lated vessels and in vivo studies, the basal release of NO
has been measured by analyzing the contractile responses
induced by NOS inhibitors. Their result suggested that2004:4 (2004) Nitric Oxide in Physiology and Pathophysiology 233
the basal formation of NO is decreased in hypertension
[71]. It has been described that the incidence of hyper-
tension as well as isolated systolic hypertension is en-
hanced in elderly persons. The older hypertensives have
a twofold greater risk of suﬀering from cardiovascular
dysfunction than do younger hypertensives. Changes in
viscoelastic properties together with augmented vascular
stiﬀness contribute to the increase in both systolic arterial
pressure and blood pressure with age [71]. The associa-
tion of hypertension with aging increases the risk of lac-
erations in the endothelial modulation of vascular tone,
which suggests that aging is an additional risk factor for
endothelial dysfunction [69].
The eﬀect of sodium nitroprusside (an NO) and NG-
monomethyl-L-arginine (L-NMMA), a speciﬁc NOS in-
hibitor, on platelet was studied, and it was observed that
inplateletsfromhypertensivepatients,thereisamarkedly
reduced sensitivity to L-NMMA, which could be ex-
plained by a reduction in NO synthesis [72]. The eﬀect of
L-arginine administration in patients with essential and
secondary hypertension was investigated by measuring
hemodynamic parameters, neuroendocrine hormones,
and indicators of NO release. During administration,
mean arterial pressure decreased, heart rate increased,
cardiac output increased, and total peripheral resistance
decreased [73]. Essential hypertension also has a genetic
basis. Accumulated evidences, including ﬁnding of eleva-
tion of arterial blood pressure in mice lacking the eNOS
gene, strongly suggest that alteration in NO metabolism
is implicated in hypertension. The Glu 298 Asp mis-sense
variant was signiﬁcantly associated with essential hyper-
tension suggesting that it is a genetic susceptibility factor
for essential hypertension [74].
Recently, Das [75] has beautifully summarized the
overall role of NO and O
−·
2 in hypertension. In general,
it is reported that patients with uncontrolled essential
hypertension have elevated concentrations of superox-
ide anion (O
−·
2 ), H2O2, lipid peroxides, endothelin, and
transforming growth factor-beta (TGF-beta) with a si-
multaneous decrease in endothelial NO (eNO), SOD,
vitamin E, and long-chain polyunsaturated fatty acids
(LCPUFAs). Physiological concentrations of angiotensin
II activate NAD(P)H oxidase and trigger free radical gen-
eration (especially that of O
−·
2 ). Normally, angiotensin
II-induced oxidative stress is abrogated by adequate pro-
duction and release of eNO, which quenches O
−·
2 to
restore normotension. Angiotensin II also stimulates the
production of endothelin and TGF-beta. TGF-beta en-
hances NO generation, which in turn suppresses TGF-
beta production. Thus, NO has a regulatory role on TGF-
beta production and is also a physiological antagonist of
endothelin. Antihypertensive drugs suppress the produc-
tion of O
−·
2 and TGF-beta and enhance eNO synthesis to
bring about its beneﬁcial actions. LCPUFAs suppress ACE
activity, reduce angiotensin II formation, enhance eNO
generation, and suppress TGF-beta expression. Prenatal
supplementation of LCPUFAs decreases insulin resistance
and prevents the development of hypertension in adult
life,whereasdeﬁciencyofLCPUFAsintheprenatalperiod
results in raised blood pressure later in life. Patients with
essential hypertension have low concentrations of various
LCPUFAsintheirplasmaphospholipidfraction.Basedon
this, it is proposed that LCPUFAs serve as endogenous
regulators of ACE activity, O
−·
2 and eNO generation, and
TGF-betaexpression.Itisproposedthatavailabilityofad-
equate amounts of LCPUFAs during the critical periods
of growth prevents the development of hypertension in
adulthood [75].
Pulmonary arterial hypertension (PAH) is a disease
of the pulmonary vasculature leading to vasoconstriction
and remodeling of the pulmonary arteries. The result-
ing increase in the right ventricular after load leads to
right ventricular failure and death [76]. NO administra-
tion restored the stroke volume with a decrease in PAH
andanimprovementofthepulmonaryvascularresistance
to systemic vascular resistance ratio. Systemic blood pres-
sure and coronary perfusion remained unaﬀected. This
selective eﬀect on the pulmonary circulation should be
considered a major advantage of NO inhalation in the
treatment of right ventricular dysfunction in acute pul-
monary hypertension [76]. Severe pulmonary hyperten-
sion and right-sided circulatory failure (RSCF) represent
anincreasingcauseofmorbidityandmortalityinpatients
undergoing high-risk cardiac surgery [77]. Increased pul-
monary vascular resistance in the setting of cardiopul-
monary bypass (CPB) may further lead to decrease in
blood ﬂow across the pulmonary vascular bed; thereby
decreasing left ventricular ﬁlling and cardiac output. Cur-
rent management techniques for RSCF include both non-
speciﬁc vasodilator and inotropic agents (often limited by
systemichypotension)andtheplacementofrightventric-
ularassistdevices(associatedwithincreasedperioperative
morbidity).InhaledNO(NOi)representsanovel,speciﬁc
pulmonaryvasodilatorthathasbeenproveneﬃcaciousin
these clinical settings [77].
The role of the NO pathway in both the healthy
and the diseased pulmonary circulation is described by
Michelakis [78]. The treatment options are limited, ex-
pensive, and associated with signiﬁcant side eﬀects. The
NO pathway in the pulmonary circulation provides sev-
eral targets for the development of new therapies for this
disease. However, the NO pathway is modulated at mul-
tiple levels including transcription and expression of the
NOS gene, regulation of the NOS activity, regulation of
the production of cGMP by phosphodiesterases, postsyn-
theticoxidationofNO,andsoforth.Thismakesthestudy
of the role of the NO pathway very diﬃcult, unless one
uses multiple complementary techniques. Furthermore,
there are signiﬁcant diﬀerences between the pulmonary
and the systemic circulation, which make extrapolation of
data from one circulation to the other very diﬃcult. In
addition,theroleofNOinthedevelopmentofpulmonary
hypertension varies among diﬀerent models of the dis-
ease [78]. Recently, Huang et al [79] have suggested that234 Narendra Tuteja et al 2004:4 (2004)
chronicNOinhibitionamelioratesportal-systemicshunt-
ing and improves the collateral vascular responsiveness to
arginine vasopressin in portal hypertensive rats.
CONCLUSIONSAND PERSPECTIVES
On the basis of the survey presented in this article, we
can say that NO is a “universal messenger molecule” so
far as its spectrum of actions is concerned. This molecule
plays a vital role in a wide variety of pathophysiological
andbiochemicalreactions.Insummary,NOisinvolvedin
regulationofbloodﬂowindiﬀerentpartsofthebody,reg-
ulation of blood pressure, prevention of aggregation and
adhesion of platelets, assisting the immune system to kill
a wide variety of pathogens and block viral replication,
promotion of certain types of cancer, promotion of pe-
nile erection and spermatogenesis, and facilitating child-
birth. Common vascular disease states including hyper-
tension, atherosclerosis, and diabetes are associated with
endothelial dysfunction, characterized by reduced bioac-
tivity of NO. Loss of the vasculoprotective eﬀects of NO
contributes to disease progression, but the mechanisms
underlying endothelial dysfunction remain unclear. In-
creased superoxide production in animal models of vas-
cular disease contributes to reduced NO bioavailability,
endothelial dysfunction, and oxidative stress. In human
blood vessels, the NAD(P)H oxidase system is the prin-
cipal source of superoxide, and is functionally related to
clinical risk factors and systemic endothelial dysfunction.
NO is an important mediator of both physiologi-
cal and pathological responses. Over the past decade,
evidence has accumulated, indicating that NO plays a
key role in the regulation of metabolic and cardiovascu-
lar homeostasis. Pharmacological compounds that release
NO have been useful tools for evaluating the broad role
of NO in physiology and therapeutics. NO deﬁciency has
been implicated in the genesis and evolution of several
diseasestates.Bothmedicalneedsandcommercialoppor-
tunitieshavefosteredattemptstomodulateNOinthehu-
man body for therapeutic gain. Strategies for NO modu-
lation encompass anti-inﬂammatory, sexual dysfunction,
and cardiovascular indications. Recent insights suggest
that the original model, in which NO production reﬂects
cell-speciﬁc isoenzymes with distinct functional proper-
ties, does not adequately capture the complexity of NOS
regulation. Rather, all three NOS isoforms are constitu-
t i v e l yc o e x p r e s s e di nav a r i e t yo fc e l l sa n dr e s i d ei nm u l -
tiple subcellular compartments [4]. Indeed, the expres-
sion of NOS isoforms is transcriptionally and translation-
ally controlled, and they undergo co- and posttransla-
tional modiﬁcation, resulting in their expression in spe-
ciﬁccellularandsubcellularcompartments,inthecontext
of co-expressed regulatory partners, that precisely con-
trols the spatial and temporal production of and signaling
by NO [4].Interestingly,inplants,nitratereductaseisalso
responsibleforNOproduction[80].Variousgeneticpoly-
morphisms of the eNOS gene have been reported as sus-
ceptibility genes in a number of cardiovascular diseases.
The functional signiﬁcance of these polymorphisms has
not yet been demonstrated.
Although much is known about diﬀerent aspects of
NO, there are many aspects yet not fully understood; fur-
ther exploration of certain aspects might help in allevi-
ating many pathophysiological disorders. (i) Role of NO
within the myocardium is not fully known and is being
pursued intensively. It is anticipated that a greater under-
standing of this action will help to explain some of the
processes involved in heart diseases. (ii) So far it seems
that increased ingestion of arginine reverses the changes
in vascular reactivity and induces internal thickness in
atherosclerosis and may also reduce blood pressure and
excessive proliferation of smooth muscle cells in hyper-
tension. There may be other ways to increase active con-
centrations of endogenous NO such as by prolonging its
half-life or duration of its actions. Moreover, NO donat-
ing compounds can be used as replacement therapy to
treat its impaired production. (iii) Selective inhibition of
generation of NO may be a useful therapy as in case of
brain ischemia and chronic degenerative diseases of the
nervous system. (iv) Levels of L-Arginine-NO pathway
products in biological ﬂuids may be used as clinical mark-
ers for monitoring certain pathological conditions and
progressoftheirtreatment.(v)Immuneregulatoryaction
of NO appears to target Th1/Th2 balance of immune re-
sponses. NO can induce expression of Th2 associated cy-
tokines IL4 whereas IFNγ and IL2 are suppressed. It has
also been shown that apoptosis promoting activity of NO
also primarily aﬀects Th1 cells. These observations can
be exploited to modulate the immune system to favor-
able conditions by selective activation/inhibition of NOS.
(vi) There is enhanced expression of NOS in a variety of
human cancers. Regulation of NOS activity in such cases
mayhavetherapeuticpotential.Thisaspectneedstobese-
riously explored to pave treatment of certain carcinomas.
Wehavesuperﬁciallyscannedanumberofpathophys-
iological/biochemical areas where NO plays a direct or
indirect role. The simplicity of this molecule, contrasted
with its ubiquitous presence and complexity of its actions,
is astonishing. Further knowledge regarding regulation
of its production and signal transduction along with its
therapeutic potentials would be of much interest. Insights
into mechanisms regulating NO production and signal-
ing,andtheirintegrationintoresponsesmediatinghome-
ostasis place into speciﬁc relief the role of those processes
in pathophysiology. Moreover, this central role in patho-
physiologyidentiﬁesNOsignalingasakeytargetfornovel
therapeutic interventions to minimize irreversible tissue
damage associated with ischemic cardiovascular disease.
NO therapy has been used experimentally to successfully
treat idiopathic pulmonary hypertension and pulmonary
hypertension associated with cardiac and respiratory dis-
eases.However,thelong-termbeneﬁtshaveyettobestud-
ied. They are far from ideal because of the associated side
eﬀects mainly due to the catabolism of NO in toxic NO2.
A safer technology to regulate in vivo synthesis of NO by
genetic manipulation would be a welcome move.2004:4 (2004) Nitric Oxide in Physiology and Pathophysiology 235
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